English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Aims: Numerous studies have identified BRAF V600E  mutation as a predictive factor of anti-EGFR antibodies in colorectal cancer (CRC). However, the association between BRAF V600E  mutation and clinicopathological features remains unclear. Therefore, we aimed to conduct an updated and comprehensive meta-analysis to evaluate the above issues. Methods: We performed a systematic literature search from PubMed, Web of Science, Embase, and PMC database examining the association between BRAF V600E  mutation and clinicopathological features in CRC patients. Odds ratio with 95% confidence interval were used to estimate the effects of BRAF V600E  mutation on each clinicopathological parameter with fixed-effect model or random-effect model. Results: Sixty-one studies published, including 32407 CRC patients from multiple countries, were included in the meta-analysis. The overall BRAF V600E  mutation rate was 11.38%, and BRAF V600E  mutation was positively related to high disease stage (OR=0.81; 95% CI=0.72-0.92; P =0.001), high T stage (OR=0.51; 95% CI=0.40-0.65; P &lt;0.00001), proximal colon (OR=4.76; 95% CI=3.81-5.96; P &lt;0.00001) or right colon (OR=5.15; 95% CI=4.35-6.10, P &lt;0.00001) tumor location, poor tumor differentiation (OR=0.27; 95% CI=0.21-0.34; P &lt;0.00001), mucinous histology (OR=2.97; 95% CI=2.37-3.72; P &lt;0.00001), K-ras-wild type (OR=0.04; 95% CI=0.02-0.07; P &lt;0.00001), TP53-wild type (OR=0.50; 95% CI=0.31-0.78; P =0.003), deficient DNA mismatch repair (OR=2.93; 95% CI=1.78-4.82; P &lt;0.00001), high microsatellite instability (OR=11.15; 95% CI=8.51-14.61; P &lt;0.00001) and high CpG island methylator phenotype (OR=0.04; 95% CI=0.03-0.08; P &lt;0.00001). Conclusions: Our updated meta-analysis demonstrated that BRAF V600E  mutation was related to poor prognosis of CRC and associated with the distinct molecular phenotypes.

Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis

Clinicopathological Significance of BRAF^V600E Mutation in Colorectal Cancer: An Updated Meta-Analysis